• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Dorzolomide HCI OK for use in children

Article

The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children

AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children

Article
ROP: Treating and preventing blindness in preterm babies

ROP: Treating and preventing blindness in preterm babies

Podcast
AAO 2023: FundamentalVR and AAO team up for pediatric ophthalmic training VR program

AAO 2023: FundamentalVR and AAO team up for pediatric ophthalmic training VR program

Article
Managing a changing landscape of IRD pediatric cases

Managing a changing landscape of IRD pediatric cases

Podcast
LSL Pharma Group, Fera Pharmaceuticals announce distribution agreement to ease drug shortage in US hospitals

LSL Pharma Group, Fera Pharmaceuticals announce distribution agreement to ease drug shortage in US hospitals

Article
Potential bacterial involvement in the development of severe ROP

Potential bacterial involvement in the development of severe ROP

Article
© 2023 MJH Life Sciences

All rights reserved.